Introduction
Over the past 50 years, heart transplantation (HT) has been consolidated as the therapy of choice for patients with end-stage heart disease, provided that a careful selection process is followed to assess candidacy. According to data reported from international registries, one-year and 10-year post-transplant survival rates in the current era exceed 85% and 50%, respectively. quality of life and functional status of HT recipients also improve significantly after the intervention. Late after HT, some recipients may develop impairment of graft function, which usually leads to a clinical syndrome similar to native heart failure (HF). Late graft failure (GF) shares some underlying pathophysiological processes with native HF, but modulated by specific variables derived from the exceptional environment following HT. 2 Acute and chronic rejection are specific causes of late GF which typically affect HT recipients; these individuals, however, are also exposed to other classic risk factors for native HF like hypertension, diabetes, coronary atherosclerosis, pericardial disease, and cardiac drug toxicity.
To the best of our knowledge, only one published paper has addressed in a systematic manner the underlying mechanisms and outcomes of GF following HT; 3 this study, however, focused specifically in patients with a severely reduced left ventricular ejection fraction (LVEF). We feel that this approach is insufficient, as ventricular hypertrophy and myocardial fibrosis leading to diastolic dysfunction and GF-even with a relatively preserved systolic function-are being increasingly recognized as important facts in the natural history of HT recipients. 2 The purpose of our study was to analyse the incidence, clinical profile, underlying aetiologies and long-term clinical outcomes of symptomatic late GF in HT recipients.
Methods

Study protocol, patients and variables
We conducted a retrospective study based on the historical cohort of patients who underwent HT at our institution since the start of the program in April 1991 to December 2014. Heart transplant recipients younger than 16 years, those with second HT or multi-organ transplantation, and those who died within the in-hospital postoperative period after HT were excluded. Data were extracted from a prospectively maintained database, and subsequently completed by means of a comprehensive review of clinical records. The Regional Committee for Ethics in Clinical Investigation of A Coruña-Ferrol, Galicia, Spain, approved the study protocol. Given the retrospective, observational, non-interventional, nature of the study, patients were not asked for a specific informed consent.
Pre-transplant baseline clinical variables of recipients were considered, among those collected in the database, as the closest in time to transplantation. Data regarding donor characteristics and HT procedures were also analysed.
Definition of late graft failure
For the purpose of this study, the clinical onset of late GF was defined as the first hospital admission due to this condition after HT. The diagnosis of GF was established by the attending clinician on the basis of the presence of typical signs and symptoms of HF together with an objective evidence of a significant abnormality of the structure or function of the heart graft, which was considered responsible for the clinical syndrome (e.g. reduced LVEF, elevated filling pressures, right ventricular systolic dysfunction, etc.). As the focus of the study was late GF, this definition specifically excluded patients who developed early ('primary') graft dysfunction during the in-hospital postoperative period after HT.
In our institution, every HT recipient admitted due to new-onset GF undergoes a routine diagnostic work-up that includes laboratory tests, cardiac biomarkers, 12-lead electrocardiogram and transthoracic echocardiography. On the basis of non-invasive findings, additional studies such as endomyocardial biopsy, right heart catheterization and coronary angiography are also frequently performed in these individuals. 
Causes of graft failure
Acute cellular rejection was considered as a potential cause of GF if graded ≥1R according to the definition of the International Society for Heart and Lung Transplantation (ISHLT). 4 Similarly, antibody-mediated rejection was considered a potential cause of GF if graded ≥1 according to ISHLT consensus criteria. 5 In our institution, direct immunofluorescence tests for the detection of C4d and C3d in endomyocardial biopsy specimens are available since 2002 and 2010, respectively. Until 2001, the diagnosis of antibody-mediated rejection was mainly based on histological findings; immunofluorescence against IgG, IgM, C1q, and fibrin were then also available, but this practice was discontinued in view of its low diagnostic accuracy. Cardiac allograft vasculopathy (CAV) was considered as a potential cause of GF if detected by coronary angiography and graded ≥1 according to ISHLT criteria, 6 or if detected on the basis of autopsy findings, and interpreted as clinically significant. Constrictive pericarditis was diagnosed on the basis of typical haemodynamics or highly suggestive findings from imaging studies. Other specific underlying conditions (i.e. amyloid cardiac disease) were considered the most likely reason for GF when described as a primary diagnosis in discharge reports.
Statistical analysis
Continuous variables are presented as means ± standard deviation and categorical variables are presented as proportions. The chi-square test was used to compare the former variables, while the Student's t-test or the Mann-Whitney tests were used to compare the latter.
Patients were followed from the date of transplantation up to the date of death or cardiac re-transplantation; otherwise, follow-up was finished as of 31 August 2016. The cumulative incidence of new-onset late GF over long-term post-transplant follow-up was estimated by means of the Kaplan-Meier method. In this analysis, patients who died and had never been admitted due to late GF were censored at the time of death. Independent predictors of late GF were identified by means of multivariable backward stepwise Cox regression. Candidate variables that entered the backward stepwise model were those reflecting baseline clinical characteristics of recipients (pre-transplant), donors and heart transplant procedures that showed a statistically significant association (P<0.05) with GF in univariable analyses. To explore a potential era effect with regard to the incidence of late GF, patients were categorized in three groups according to the year of transplantation (era 1: 1991-1998, era 2: 1999-2006, era 3: 2007-2014).
Subsequent outcomes after the onset of late GF were investigated in patients who developed this complication. For this analysis, three end-points were selected: overall survival, survival free of cardiac re-transplantation, and subsequent re-hospitalizations due to decompensated HF. Independent predictors of these three outcomes were explored by means of multivariable backward stepwise Cox regression, following a similar approach to that described for the assessment of baseline predictors of new-onset late GF, with the difference that in this case candidate variables selected for Cox analyses were those reflecting clinical characteristics of patients who presented with late GF at the time of their first hospital admission due to this condition.
Finally, in order to explore the prognostic relevance of late GF on the global long-term outcomes of HT recipients, we compared Kaplan-Meier post-transplant survival curves of patients who developed late GF at any moment after HT and those of patients who did not; this comparison was conducted by means of the log-rank method.
Statistical significance was considered as a P-value of <0.05 for all contrasts. Statistical analysis was performed with SPSS 20.0 (SPSS Inc., Chicago, IL, USA).
Results
Incidence of late graft failure
From April 1991 to December 2014, 632 patients aged >16 years underwent first, single-organ, HT at our institution. Eighty-five patients (13.4%) who died during the in-hospital postoperative period were excluded from this analysis. Therefore, the surviving 547 subjects constituted the study population.
Over a mean follow-up of 8.4 ± 6 years after transplantation, 178 patients (32.5%) were hospitalized due to late GF. The incidence rate of new-onset GF in the study population was 3.6 cases [95% confidence interval (CI) 3.1-4.2] per 100 patient-years. Baseline clinical characteristics of patients who presented late GF over follow-up and those who did not, as considered at the time of transplantation, are listed in the Table 1 .
According to the Kaplan-Meier method, the cumulative probability of having been hospitalized due to late GF was 4.5%, 15.2%, 29.3%, 41.6% and 57.9% in patients surviving 1, 5, 10, 15 and 20 years after HT, respectively ( Figure 1 ).
Risk factors for late graft failure
In univariable Cox regression analysis, eight baseline clinical variable showed a statistically significant association with GF, as shown in Table 2 
Clinical presentation of patients with late graft failure
Clinical characteristics of study patients at the time of their first hospitalization due to late GF are shown in Table 3 . Most patients presented with advanced New York Heart Association class and physical signs of congestion; cardiogenic shock was present in 9% cases. History of previous treated graft rejection was noted in 65.7% patients. Mean time elapsed since transplantation to GF onset was 6.9 ± 5.5 years (range 23 days to 22.8 years). Mean duration of hospital stay was 13.8 ± 12.5 days.
Most patients showed preserved LVEF (≥50%); the prevalence of mid-range (40-49%) and depressed (<40%) LVEF was 20 
Causes of late graft failure
A diagnostic evaluation of the presence of CAV by means of coronary angiography and/or necropsy was obtained for 168 (94.4%) patients admitted due to new-onset GF; endomyocardial biopsies for the assessment of graft rejection were available in 158 (88.8%) cases. Overall, evidence of CAV was present in 90 (50.6%) patients; while cellular rejection grade ≥1R and antibody-mediated rejection grade ≥1 were demonstrated in 80 (44.9%) and 34 (19.2%) patients, respectively. Combined evidence of both CAV and either cellular and/or antibody-mediated rejection was present in 44 (24.7%) patients. Neither CAV nor rejection could be demonstrated in 32 subjects (18%).
Other specific underlying causes of late GF in the study population were constrictive pericarditis (n=9), pericardial effusion (n=3), alcohol toxicity (n=1), and light-chain amyloid heart disease (n=1).
Therapy in patients with late graft failure
A summary of therapies administered to HT recipients admitted due to new-onset GF is presented in Table 3 . Intravenous corticosteroids for suspected or proven acute rejection were administered in 108 (60.7%) cases. Plasmapheresis was used in 34 (19.1%) patients who showed signs of antibody-mediated rejection; 15 (8.4%) of these individuals also received rituximab. Thymoglobulin and muromonab-CD3 were administered to 4 (2.2%) and 3 (1.7%) patients with refractory acute rejection, respectively. Forty-six patients (25.8%) had a significant change of previous maintenance immunosuppressive regimen -cyclosporine A to tacrolimus switch in 23 cases, azathioprine to mycophenolate mofetil switch in 7 cases, and initiation of everolimus or sirolimus in 15 cases.
Twenty-four (13.5%) patients required inotropic support during admission. Non-pharmacological therapies like mechanical ventilation, mechanical circulatory support, intracardiac device implantation, coronary revascularization, and surgical procedures like pericardiectomy or valve replacement were occasionally required ( Table 3) .
Outcomes after late graft failure onset
Mean follow-up after late GF diagnosis was 3.5 ± 3.9 years. Over this period, 108 (60.7%) patients died and 10 (5.6%) patients underwent cardiac re-transplantation. Thirteen (7.3%) patients died and 2 (1.1%) patients were re-transplanted during the index hospitalization. As shown in Figure 3 , re-transplant-free survival 1, 5, 10 and 15 years after GF diagnosis was 72.2%, 38.4%, 18.4%, and 7.5%, respectively ( Figure 3A) ; overall survival at same time points was 74.6%, 43.5%, 22.2% and 11.2%, respectively ( Figure 3B) .
Over long-term follow-up after discharge, 234 subsequent re-hospitalizations due to decompensated, symptomatic HF occurred in 108 (66.3%) patients, resulting in an incidence rate of 40.9 (95% CI 36.6-46.1) episodes per 100 patient-years. Time from transplantation to death, re-transplantation or last follow-up (years) 10.5 ± 6.1 9.9 ± 5.9 0.318 Time from transplantation to graft failure, death, re-transplantation or last follow-up (years) 6.9 ± 5.5 9.9 ± 5.9 <0.001 Figure 1 Cumulative probability of hospitalization due to new-onset, symptomatic late graft failure among 547 first, single-organ, heart transplant recipients who survived the early postoperative period: Kaplan-Meier analysis.
Kaplan-Meier estimation of the cumulative probability of re-hospitalization due to decompensated HF after discharge is represented in Figure 3C .
Predictors of outcome after late graft failure onset
In univariable Cox regression analyses, several clinical variables showed a statistically significant association with overall survival and re-transplant free survival after late GF onset. However, only 5 of them remained as statistically significant, independent predictors of both outcomes in backward stepwise multivariable analyses ( Table 4) . and lower LVEF were independently associated with higher risk of death and higher risk of the composite outcome of death or cardiac re-transplantation. The presence of CAV and the need for inotropes were also independently associated with a higher risk of re-admission due to decompensated HF after hospital discharge ( Table 4) . Antibody-mediated rejection ≥1 was associated with higher mortality in univariable analysis; however, this finding was no longer an independent predictor of mortality after multivariable adjustment. Figure 4 shows a comparison of global post-transplant outcomes in patients who were hospitalized due to late GF at any time during long-term post-transplant follow-up and patients who did not ('controls'). In comparison to controls, patients admitted due to GF had statistically significant shorter re-transplant free survival (log-rank, P=0.003) and overall post-transplant survival (log-rank, P=0.024).
Impact of late graft failure on global post-transplant outcomes
Discussion
In this single-centre study of 547 consecutive patients discharged alive after orthotopic HT, the annualized cumulative incidence rate of hospital admission due to new-onset late GF was 3.6%. Subsequent clinical outcomes after GF onset were poor, with a 5-year survival rate lower than 50%, and annualized rates of re-hospitalization due to decompensated HF higher than 40%. Cardiac allograft vasculopathy and acute rejection were the most frequent presumed causes of GF in our cohort.
The cumulative incidence of late GF observed in our study indicates that HT recipients are exposed to a significant risk of suffering this condition. Making an analogy with native HF, this figure might be comparable, for example, to the risk of symptomatic HF in 178 heart transplant recipients hospitalized due to new-onset, symptomatic late graft failure.
patients with type 2 diabetes 7 and only slightly lower than the one of subjects with asymptomatic left ventricular systolic dysfunction. 8 Interestingly, the incidence of GF in HT recipients was linear over time, as it remained almost unchanged up to more than 20 years of follow-up after the operation.
In our cohort, three baseline clinical variables were independently associated with an increased risk of late GF. Diabetes mellitus is a well-established risk factor for native HF, mainly through an increased risk of epicardial coronary artery disease, but also due to microvascular dysfunction and primary myocardial damage. 9 Heart transplant recipients with diabetes mellitus are especially prone to CAV, 10 which constituted the most frequent presumed cause of GF in our study. A small donor-recipient weight ratio carries an increased risk of postoperative graft dysfunction and death after HT.
11 Undersized hearts are also predisposed to chronic sinus tachycardia, a phenomenon associated with increased risk of late graft dysfunction and reduced survival. 12 Finally, high pre-transplant transpulmonary pressure gradient is also a consolidated risk factor for graft dysfunction and mortality after HT, both during the early postoperative period 13 and late follow-up.
14
Heart transplant recipients admitted due to new-onset GF showed significant heterogeneity in their clinical presentation. Most of them showed physical signs of congestion, but the severity of the clinical picture ranged from moderate effort dyspnoea to critical cardiogenic shock. Interestingly, the initial echocardiographic assessment revealed a preserved (≥50%) or mid-range (40-49%) LVEF in the majority of cases; an overtly reduced LVEF (<40%) was only noted in 19%. Indeed, advanced diastolic dysfunction (i.e. restrictive physiology) and right ventricular systolic dysfunction were more common findings than left ventricular systolic dysfunction in these individuals. Left ventricular enlargement was also infrequently detected. These observations should be put in the context of the contemporary concept of chronic heart graft dysfunction, a multi-factorial condition with several underlying . Acute rejection and CAV were the most frequent presumed underlying aetiologies of GF in our population; objective evidence of CAV, cellular rejection and antibody-mediated rejection was obtained in 51%, 45% and 19% patients, respectively. Notwithstanding this, it is remarkable that neither CAV nor rejection could be identified in almost 1 out of 5 HT recipients admitted due to new-onset GF. In this sense, the limited sensitivity of standard ancillary methods for the detection of CAV (coronary angiography) 18 and acute rejection (endomyocardial biopsy) 19 should be recognized, as it may have led to a significant proportion of false negatives. In the other hand, CAV, cellular rejection and antibody-mediated rejection may also coexist in a single patient; indeed, it is hard in some cases to identify a single underlying aetiology as the certain cause of graft dysfunction. In clinical practice, transplant doctors must often deal with such diagnostic uncertainty; it is frequent, for example, that the initial therapeutic approach when facing a HT recipient with new-onset GF is to enhance immunosuppression empirically (e.g. administering intravenous corticosteroids), even before a conclusive diagnosis of acute rejection can be made.
Our findings regarding presumed underlying aetiologies of GF are in general consistent with those reported by Shahzad et al. 3 However, there are some remarkable differences between this previous study and ours. more than 80% of patients presenting with late GF in our cohort. Second, they tried to assign graft dysfunction to a single underlying aetiology-cellular rejection, antibody-mediated rejection, CAV or unexplained-in every studied patient; given the reasons exposed previously, this point is somehow debatable. Finally, early postoperative graft dysfunction was also considered in their analysis, but excluded from the definition of GF in ours. Clinical outcomes of HT recipients admitted due to new-onset GF were poor in our study. Acute in-hospital mortality reached 7%; estimated 5-year and 10-year survival rates dropped to 43% and 22%, respectively. Subsequent hospital readmissions due to decompensated HF were very frequent among survivors. As a result, patients who developed late GF at any time after postoperative hospital discharge showed statistically significant lower overall long-term post-transplant survival than patients who did not. Outcomes were worst in patients with evidence of CAV and/or antibody-mediated rejection and in those with lower LVEF; even so, recipients with other underlying aetiologies were still exposed to significant risk.
Our results indicate that late GF is, in its different forms of presentation, a severe disease. They also reflect the lack of effective therapeutic options to treat this life-threatening condition. Until now, no solid evidence supports the use of conventional HF medications in HT recipients. Historically, the use of beta-blockers in these individuals has been concerned due to a higher predisposition to side effects; 20 however, recent data suggest that these drugs might have a positive impact on long-term post-transplant outcomes, possibly driven by a beneficial effect of heart rate reduction. 21 Treatment of acute cellular rejection remains essentially as an empirical issue, as rescue immunosuppressive therapies like intravenous steroids or thymoglobulin have never been tested in a randomized clinical trial. In recent years, protocols for the management of antibody-mediated rejection incorporated a wide variety of novel therapeutic options, including the routine use of plasmapheresis, immunoabsortion and monoclonal antibodies; however, mortality remains high in these individuals. 22 Finally, patients with established CAV are often treated with m-TOR inhibitors and coronary revascularization; however, no significant benefit of these interventions in terms of hard clinical outcomes has been proven until now. 23 Once advanced CAV has developed, only cardiac re-transplantation might improve survival in highly selected candidates, but results remain controversial. 24 Our study has a few limitations. First, this is a retrospective analysis, which therefore may be affected by the selection, information and confusion biases inherent to this type of studies. Second, it is limited to a single institution, so its external validity cannot be guaranteed. Third, the study addressed a long period of time, along which there were significant changes in candidate selection, complementary tests, immunosuppressive regimens and treatment protocols; the lack of longitudinal data about these aspects is another limitation of the present investigation. Fourth, the exclusion of patients who died within the early postoperative period resulted in survival bias, so data presented in our study cannot be used to assess aggregate post-transplant risk. Finally, diagnostic tests performed to assess graft function and underlying aetiologies were driven by clinical judgment, and not by a pre-specified protocol; because of this, data regarding the presumed causes of GF must be interpreted with caution.
. 
Conclusions
Heart transplant recipients are exposed to a significant risk of late GF, which is, in most cases, a consequence of acute rejection or CAV. In our cohort, LVEF was preserved at the initial echocardiographic evaluation in more than a half of patients admitted due to new-onset late GF; restrictive physiology and right ventricular systolic dysfunction were frequently described. Irrespective of the underlying cause, clinical outcomes following the diagnosis of late GF were poor, so as reflecting a lack of effective therapeutic interventions to treat this life-threatening condition.
